Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Jürgen K. Rockstroh"'
Autor:
Martin Gartland, Juan Sierra Madero, Andrea Antinori, Brian Wynne, Jean van Wyk, Pedro Cahn, Keith A. Pappa, Choy Y. Man, Pierre-Marie Girard, Mark R. Underwood, Daisy J. Brandon, Lloyd Curtis, Roberto Ortiz, Jose R. Arribas, Chien-Ching Hung, Jürgen K. Rockstroh, Michael Aboud, Jörg Sievers, Amanda Clarke, Rimgaile Urbaityte, Kimberly Y. Smith
Publikováno v:
AIDS (London, England)
To assess efficacy and safety of dolutegravir (DTG) + lamivudine (3TC) vs. DTG + tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naive adults with HIV-1 in the prespecified 144-week secondary analyses of GEMINI-1 and GEMINI-2.Desig
Autor:
David L. Wyles, Yves Horsmans, Erica Villa, Sarah Kopecky-Bromberg, Tania M. Welzel, Armen Asatryan, Preethi Krishnan, Federico J. Mensa, Stephen D. Ryder, Roger Trinh, Ola Weiland, David Mutimer, Peter Ruane, Stanley Wang, Edward Gane, Teresa I. Ng, Jürgen K. Rockstroh, Sandra S. Lovell, Zhenyi Xue, Jeong Heo, Kosh Agarwal, Paul Y. Kwo, Steven L. Flamm
Publikováno v:
Journal of Viral Hepatitis
Journal of viral hepatitis, Vol. 26, no. 3, p. 337-349 (2019)
Journal of viral hepatitis, Vol. 26, no. 3, p. 337-349 (2019)
Summary Glecaprevir coformulated with pibrentasvir (G/P) is approved to treat hepatitis C virus (HCV) infection and was highly efficacious in phase 2 and 3 studies. Treating HCV genotype (GT) 3 infection remains a priority, as these patients are hard
Autor:
Christoph Boesecke, Alexander Thielen, Klaus Jansen, Anders Boyd, P. Ingiliz, Stefan Mauss, Britt Skaathun, Natasha K. Martin, Matthias an der Heiden, Knud Schewe, Thomas A. Lutz, Stefan Christensen, Jürgen K. Rockstroh, Axel Baumgarten
Publikováno v:
Journal of infectious diseases, 220(10), 1635-1644. Oxford University Press
J Infect Dis
J Infect Dis
Background Despite high hepatitis C virus (HCV) treatment rates, HCV incidence among human immunodeficiency virus (HIV)–infected men who have sex with men (HIV-infected MSM) in Germany rose before HCV direct-acting antivirals (DAAs). We model what
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::470bd0fe3668ae71e1bf41b5562efbad
https://pure.amc.nl/en/publications/eliminating-hepatitis-c-virus-among-human-immunodeficiency-virusinfected-men-who-have-sex-with-men-in-berlin(28b146ae-aa81-4f95-a021-71fac4b13353).html
https://pure.amc.nl/en/publications/eliminating-hepatitis-c-virus-among-human-immunodeficiency-virusinfected-men-who-have-sex-with-men-in-berlin(28b146ae-aa81-4f95-a021-71fac4b13353).html
Autor:
Jürgen K. Rockstroh, S Schlabe
Publikováno v:
Expert Opinion on Pharmacotherapy. 19:49-64
Direct-acting antivirals (DAA) have revolutionized the modern treatment of chronic hepatitis C (HCV). These highly efficacious, well-tolerated, all-oral HCV regimens allow cure of HCV in over 95% of HCV-monoinfected as well as HIV/HCV-coinfected pati
Autor:
Maja A. Sommerfelt, Gonzalo Tapia, Yunda Huang, Arnt-Ove Hovden, Mats Ökvist, Richard B. Pollard, Brittany Sanchez, Giuseppe Pantaleo, Lily Zhang, Jürgen K. Rockstroh, Monica Trondsen
Publikováno v:
EBioMedicine, Vol 24, Iss C, Pp 195-204 (2017)
EBioMedicine, vol. 24, pp. 195-204
EBioMedicine
EBioMedicine, vol. 24, pp. 195-204
EBioMedicine
Background In a placebo-controlled trial of the peptide-based therapeutic HIV-1 p24Gag vaccine candidate Vacc-4x, participants on combination antiretroviral therapy (cART) received six immunizations over 18 weeks, followed by analytical treatment int
Autor:
Christoph Boesecke, Jürgen K. Rockstroh, Robert H. Hyland, Thomas A. Lutz, Patrick Ingiliz, Hadas Dvory-Sobol, Chohee Yun, Wei Zheng, Diana M. Brainard, Mark Nelson, Sanjay Bhagani
Publikováno v:
The Lancet Gastroenterology & Hepatology. 2:347-353
Summary Background The latest European Association for the Study of the Liver (EASL) guidelines now recommend that patients with acute hepatitis C virus (HCV) infection should be treated with a combination of sofosbuvir and an NS5A inhibitor for 8 we
Autor:
Natalia Zakharova, Hugo Cheinquer, Peter Ackerman, Dennis Hernandez, Jürgen K. Rockstroh, Mark S. Sulkowski, Christophe Moreno, Gail V. Matthews, Adriano Lazzarin, Federico Pulido, Antonio Rivero, Adrián Gadano, Douglas T. Dieterich, Eric Hughes, Juan Berenguer, Pierre Côté, Zhaohui Liu, Timothy Eley, Walford J. Fessel, Jean-Michel Molina, Patricia Mendez, Juan A. Pineda, Stephanie Noviello, Fiona McPhee
Publikováno v:
Hepatology International. 11:188-198
Daclatasvir (DCV) is a potent, pangenotypic, hepatitis C virus (HCV) non-structural protein 5A inhibitor with low potential for drug interactions with antiretroviral therapy (ART). We evaluated the safety and efficacy of DCV plus peginterferon alfa-2
Autor:
David A. Cooper, Marcelo H. Losso, Richard Harrigan, Sean Emery, Waldo H. Belloso, Janaki Amin, Thierry Prazuck, Ian Woolley, Amanda Clarke, Martin Fisher, Patrick W. G. Mallon, Andrejz Horban, John Gill, Sarah Pett, Anthony D. Kelleher, José M. Gatell, Rolf Kaiser, Wataru Sugiura, Kiat Ruxrungtham, David Silk, Norma Porteiro, Jaime Andrade-Villanueva, J.A. Arnaiz, Elise Tu, Andrew Clark, Juan Sierra Madero, Marcelo Wolff, Jürgen K. Rockstroh
Publikováno v:
Clinical Infectious Diseases. 63:122-132
Background. Alternative combination antiretroviral therapies in virologically suppressed human immunodeficiency virus (HIV)-infected patients experiencing side effects and/or at ongoing risk of important comorbidities from current therapy are needed.
Autor:
Patrick Ingiliz, Yue Zhao, Maria Jesus Jimenez-Exposito, Tania M. Welzel, Jürgen K. Rockstroh, Marc van der Valk, Markus Peck-Radosavljevic, Jörg Petersen, Stefan Zeuzem
Publikováno v:
Antiviral therapy, 22(3), 225-236. International Medical Press Ltd
Background HIV–HCV-coinfected patients respond just as well to modern direct-acting antiviral HCV therapy as HCV-monoinfected patients. However, clinical data for all-oral HCV treatments are sparse in HIV–HCV-coinfected patients with an advanced
Autor:
Jürgen K. Rockstroh, Jenny Bischoff
Publikováno v:
International journal of antimicrobial agents. 56(1)
Direct-acting antivirals (DAAs) have tremendously improved the treatment of hepatitis C virus (HCV) infections also in human immunodeficiency virus (HIV)-positive individuals. Curing HCV infection is of particular importance in HIV-positive individua